NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
For more information regarding accessibility, please use the following form to contact us
* denotes a required field